Achillion Pharmaceuticals has announced dosing of the first healthy volunteer in a Phase 1 multiple ascending dose (MAD) study of ACH-5228, one of the company’s next-generation oral, small-molecule factor D inhibitors.

“This important clinical milestone for our next-generation oral factor D inhibition program marks an exciting time at Achillion as we pursue safe, effective and innovative treatments for patients with complement-mediated diseases,” said Steven Zelenkofske D.O., Executive Vice President, Chief Medical Officer at Achillion.